US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% NVDA $233.95 ▲+0.00% JNJ $256.03 ▲+0.00% SNDK $1,719.99 ▲+0.00%
FinancialContent

Articles published by KALA BIO, Inc.

News headline image
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces Reverse Stock Split
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
From KALA BIO, Inc.
Via GlobeNewswire
Tickers CSE:TRIP KALA TRUFF
News headline image
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
From KALA BIO, Inc.
Via GlobeNewswire
Tickers CSE:TRIP KALA TRUFF
News headline image
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Settles Approximately $10.6 million of Debt
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO to Present at Jefferies Global Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces Chief Executive Officer Transition
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Announces $10,750,000 Private Placement
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA
News headline image
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
Tickers KALA